Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.

Ebert MP, Meindl-Beinker NM, Gutting T, Maenz M, Betge J, Schulte N, Zhan T, Weidner P, Burgermeister E, Hofheinz R, Vogel A, Angermeier S, Bolling C, de Wit M, Jakobs R, Karthaus M, Stocker G, Thuss-Patience P, Leidig T, Gaiser T, Kather JN, Haertel N

Open source

DOI: 10.1016/s2666-7568(22)00116-7
Published: 2022 Jun
Container: The lancet. Healthy longevity
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2666-7568-22-00116-7,
  title = {Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.},
  author = {Ebert MP and Meindl-Beinker NM and Gutting T and Maenz M and Betge J and Schulte N and Zhan T and Weidner P and Burgermeister E and Hofheinz R and Vogel A and Angermeier S and Bolling C and de Wit M and Jakobs R and Karthaus M and Stocker G and Thuss-Patience P and Leidig T and Gaiser T and Kather JN and Haertel N},
  year = {2022},
  journal = {The lancet. Healthy longevity},
  doi = {10.1016/s2666-7568(22)00116-7},
  url = {https://doi.org/10.1016/s2666-7568(22)00116-7}
}

RIS

TY  - JOUR
TI  - Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.
AU  - Ebert MP
AU  - Meindl-Beinker NM
AU  - Gutting T
AU  - Maenz M
AU  - Betge J
AU  - Schulte N
AU  - Zhan T
AU  - Weidner P
AU  - Burgermeister E
AU  - Hofheinz R
AU  - Vogel A
AU  - Angermeier S
AU  - Bolling C
AU  - de Wit M
AU  - Jakobs R
AU  - Karthaus M
AU  - Stocker G
AU  - Thuss-Patience P
AU  - Leidig T
AU  - Gaiser T
AU  - Kather JN
AU  - Haertel N
PY  - 2022
JO  - The lancet. Healthy longevity
DO  - 10.1016/s2666-7568(22)00116-7
UR  - https://doi.org/10.1016/s2666-7568(22)00116-7
ER  -

APA

MP, E., NM, M., T, G., M, M., J, B., N, S., T, Z., P, W., E, B., R, H., A, V., S, A., C, B., M, D. W., R, J., M, K., G, S., P, T., T, L., T, G., JN, K., & N, H. (2022). Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.. The lancet. Healthy longevity. https://doi.org/10.1016/s2666-7568(22)00116-7

Source records

pubmed · retrieved 2026-09-26T08:20:24.495Z